Group 1 - The core viewpoint of the news is that 开拓药业-B (09939) has seen a significant stock price increase of over 8% following the announcement of the completion of a long-term safety trial for its new tyrosinase inhibitor, KT-939, which is designed to inhibit melanin production [1][2] - KT-939 has successfully completed the enrollment of 130 participants in its human safety trial, demonstrating effective inhibition of tyrosinase and showcasing antioxidant and anti-inflammatory properties, which are advantageous for cosmetic efficacy and safety [1] - The company is preparing for the registration application of KT-939, aiming to submit it to the Chinese drug regulatory authority in the third quarter of next year, following positive results from multiple safety and toxicology assessments [1] Group 2 - KT-939 is positioned to become the first domestically developed whitening cosmetic ingredient approved in China, marking a significant milestone in achieving complete independent intellectual property rights in this field [2] - The approval of a similar tyrosinase inhibitor, Thiamidol, in November 2024, highlights the potential market opportunity for KT-939, as it could provide a new option for the domestic and global skin whitening cosmetic market [2]